Infinity Pharmaceuticals | INFI - Pre Tax Profit


Infinity Pharmaceuticals reported $-9.96M in Pre-Tax Profit for its fiscal quarter ending in June of 2023.





Pre Tax Profit Change Date
AbbVie USD 5.57B 2.9B Mar/2026
Alterity Therapeutics Limited AUD -4.74M 3.53M Dec/2024
Amgen USD 1.51B 2.41B Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Cipla INR 7.49B 4.2B Mar/2026
Clal Biotechnology ILS 86.82M 17.9M Dec/2022
Compugen USD 56.84M 63.78M Dec/2025
CSL USD 2.61B 1.21B Dec/2025
Eisai JPY -7.94B 29.94B Mar/2026
Eli Lilly USD 8.27B 1.03B Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Grifols EUR 257.85M 190.87M Dec/2024
Incyte USD 343.6M 46.34M Mar/2026
Infinity Pharmaceuticals USD -9.96M 1.09M Jun/2023
Ionis Pharmaceuticals USD -93M 135M Mar/2026
J&J USD 7.82B 2.86B Mar/2026
Novartis USD 3.84B 802M Mar/2026
Pfizer USD 5.18B 6.82B Mar/2026
Plus Therapeutics USD -5.71M 1.29M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
TG Therapeutics USD 20.36M 24.73M Mar/2026